BR112020000099A2 - forma cristalina de n-[1-(5-ciano-piridin-2-ilmetil)-1h-pirazol-3-il]-2-[4-(1-trifluorometil-ciclopropil)-fenil]-acetamida, e, composição farmacêutica. - Google Patents

forma cristalina de n-[1-(5-ciano-piridin-2-ilmetil)-1h-pirazol-3-il]-2-[4-(1-trifluorometil-ciclopropil)-fenil]-acetamida, e, composição farmacêutica. Download PDF

Info

Publication number
BR112020000099A2
BR112020000099A2 BR112020000099-0A BR112020000099A BR112020000099A2 BR 112020000099 A2 BR112020000099 A2 BR 112020000099A2 BR 112020000099 A BR112020000099 A BR 112020000099A BR 112020000099 A2 BR112020000099 A2 BR 112020000099A2
Authority
BR
Brazil
Prior art keywords
crystalline form
trifluoromethyl
pyrazol
cyclopropyl
pyridin
Prior art date
Application number
BR112020000099-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Bibia Heidmann
Markus Von Raumer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of BR112020000099A2 publication Critical patent/BR112020000099A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112020000099-0A 2017-07-05 2018-07-04 forma cristalina de n-[1-(5-ciano-piridin-2-ilmetil)-1h-pirazol-3-il]-2-[4-(1-trifluorometil-ciclopropil)-fenil]-acetamida, e, composição farmacêutica. BR112020000099A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017066806 2017-07-05
EPPCT/EP2017/066806 2017-07-05
PCT/EP2018/068087 WO2019008034A1 (en) 2017-07-05 2018-07-04 CRYSTALLINE FORM OF N- [1- (5-CYANO-PYRIDIN-2-YLMETHYL) -1H-PYRAZOL-3-YL] -2- [4- (1-TRIFLUOROMETHYL-CYCLOPROPYL) -PHENYL] -ACETAMIDE

Publications (1)

Publication Number Publication Date
BR112020000099A2 true BR112020000099A2 (pt) 2020-07-07

Family

ID=63079885

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020000099-0A BR112020000099A2 (pt) 2017-07-05 2018-07-04 forma cristalina de n-[1-(5-ciano-piridin-2-ilmetil)-1h-pirazol-3-il]-2-[4-(1-trifluorometil-ciclopropil)-fenil]-acetamida, e, composição farmacêutica.

Country Status (17)

Country Link
US (2) US11059803B2 (enExample)
EP (1) EP3649117B1 (enExample)
JP (2) JP2020525475A (enExample)
KR (1) KR102645911B1 (enExample)
CN (1) CN110831932A (enExample)
AU (1) AU2018296423B2 (enExample)
BR (1) BR112020000099A2 (enExample)
CA (1) CA3067489A1 (enExample)
CL (1) CL2020000002A1 (enExample)
EA (1) EA202090193A1 (enExample)
IL (1) IL271764B2 (enExample)
MA (1) MA50972A (enExample)
MY (1) MY206357A (enExample)
PH (1) PH12020500040A1 (enExample)
SG (1) SG11201912881SA (enExample)
UA (1) UA126582C2 (enExample)
WO (1) WO2019008034A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI808952B (zh) 2016-12-16 2023-07-21 瑞士商愛杜西亞製藥有限公司 包含t型鈣通道阻斷劑之醫藥組合
CN110234622B (zh) 2017-02-06 2023-07-04 爱杜西亚药品有限公司 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法
KR102645911B1 (ko) * 2017-07-05 2024-03-08 이도르시아 파마슈티컬스 리미티드 N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태
US20230047102A1 (en) 2019-12-20 2023-02-16 Idorsia Pharmaceuticals Ltd Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
CN118202050A (zh) * 2021-08-17 2024-06-14 韩国科学技术院 靶向cav3.1基因的反义寡核苷酸及其用途
WO2023240205A1 (en) 2022-06-10 2023-12-14 Neurocrine Biosciences, Inc. Deuterated compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015270118C1 (en) 2014-06-03 2019-11-28 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as T-type calcium channel blockers
JP6500092B2 (ja) 2014-09-15 2019-04-10 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｔ型カルシウムチャンネルブロッカーとしてのトリアゾール化合物
TWI808952B (zh) 2016-12-16 2023-07-21 瑞士商愛杜西亞製藥有限公司 包含t型鈣通道阻斷劑之醫藥組合
CN110234622B (zh) 2017-02-06 2023-07-04 爱杜西亚药品有限公司 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法
KR102645911B1 (ko) * 2017-07-05 2024-03-08 이도르시아 파마슈티컬스 리미티드 N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태

Also Published As

Publication number Publication date
US11555025B2 (en) 2023-01-17
UA126582C2 (uk) 2022-11-02
WO2019008034A1 (en) 2019-01-10
SG11201912881SA (en) 2020-01-30
EA202090193A1 (ru) 2020-06-03
JP2023123679A (ja) 2023-09-05
MA50972A (fr) 2020-10-14
US20200165221A1 (en) 2020-05-28
US11059803B2 (en) 2021-07-13
MY206357A (en) 2024-12-12
JP2020525475A (ja) 2020-08-27
CN110831932A (zh) 2020-02-21
IL271764B1 (en) 2023-06-01
IL271764A (en) 2020-02-27
EP3649117B1 (en) 2024-10-09
CA3067489A1 (en) 2019-01-10
KR102645911B1 (ko) 2024-03-08
CL2020000002A1 (es) 2020-07-31
US20210300894A1 (en) 2021-09-30
KR20200018698A (ko) 2020-02-19
PH12020500040A1 (en) 2020-10-12
IL271764B2 (en) 2023-10-01
AU2018296423A1 (en) 2020-02-20
AU2018296423B2 (en) 2022-07-28
EP3649117A1 (en) 2020-05-13

Similar Documents

Publication Publication Date Title
BR112020000099A2 (pt) forma cristalina de n-[1-(5-ciano-piridin-2-ilmetil)-1h-pirazol-3-il]-2-[4-(1-trifluorometil-ciclopropil)-fenil]-acetamida, e, composição farmacêutica.
KR102825246B1 (ko) 테르페닐 화합물의 신규 염
RU2728827C2 (ru) Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения
CA2995361A1 (en) Salts of an lsd1 inhibitor
AU2018251119B2 (en) Opioid receptor (MOR) agonist salt, fumarate salt I crystal form thereof and preparation method thereof
EP3433233B1 (en) Novel crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine salt
TWI772424B (zh) 一種苯并呋喃類衍生物游離鹼的晶型及製備方法
WO2020151746A1 (zh) 1,2,3-三氮唑并[1,5-a]吡嗪类衍生物的晶型及其制备方法
IL291855A (en) Solid forms of [(1 s)-1 -[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
WO2009105751A1 (en) Acylsulfonamides and processes for producing the same
US9533953B2 (en) Method of preparation of crystal forms of 4-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxidopyridyn-4-yl)-5-methoxypyridine-2-carboxamide and crystal forms thereof
US9920045B2 (en) Solid state forms of a PDE10 inhibitor
KR102587705B1 (ko) 피페라진 화합물의 신규 결정
TW202016099A (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
CN111902406B (zh) 氮杂双环基取代的三唑类衍生物的可药用盐、晶型及制备方法
HK40009119A (en) Crystal of benzofuran derivative free base and preparation method
HK40009119B (en) Crystal of benzofuran derivative free base and preparation method
BR112019004845B1 (pt) Forma cristalina de cloridrato de éster butílico de ácido 4-((r)-2-{[6-((s) -3-metoxi-pirrolidin-1-il)-2-fenilpirimidina-4 carbonil]-amino}-3-fosfono-propionil)- piperazina-1-carboxílico, usos da mesma e de éster butílico de ácido 4-((r)-2-{[6- ((s)-3-metoxi-pirrolidin-1-il)-2- fenil-pirimidina-4-carbonil]-amino}-3- fosfonopropionil)-piperazina-1-carboxílico, ou um sal farmaceuticamente aceitável do mesmo, processos para preparação da mesma, e, composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]